Logo

Kintor Pharma Receives NMPA’s IND Clearance for KX-826 to Treat Male Androgenetic Alopecia (AGA)

Share this

Kintor Pharma Receives NMPA’s IND Clearance for KX-826 to Treat Male Androgenetic Alopecia (AGA)

Shots:

  • The NMPA has cleared an IND application for a P-III study to evaluate the efficacy and safety of KX-826 in patients with male AGA across 20+ sites in China. The first patient is expected to enroll in early Jan 2022
  • The 1EPs of the trial is the change from baseline in non-vellus TAHC at the end of 24wks.
  • On  Sept 08, 2021, the P-II trial meet its 1EPs & demonstrated a good efficacy and safety profile of KX-826. On Jul 11, 2021, the therapy has received the US FDA’s approval for AGA

Ref: Kintor Pharma | Image: Kintor Pharma

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions